|Last Price$1.76||Day Change (%)2.33%|
|Open Price$1.70||Day Change ($)0.04|
|Day Range1.68–1.76||52-Week Range1.35–8.41|
As of Wed 11/26/2014 04:51 PM EST | USD
Exelixis Announces Positive Preliminary Data From an Investigator-Sponsored Phase 1 Trial of XL888 and Vemurafenib
Research and Markets: Global Papillary Thyroid Cancer therapeutics Pipeline Report H2 2014 - Analysis of 6 Companies & 8 Drug Profiles
Research and Markets: Global Retail Logistics Market 2014-2018: Key Vendors Are FedEx, Kuehne + Nagel, Schneider and United Parcel Service
The lack of early success in its lead drug's cancer trial scares the market, but we see a buying opportunity.
Lack of competitive advantages may mean these companies aren't the bargains they seem to be.
We see opportunity as fleeing investors trigger an irrational sell-off.
Morningstar analysts see pharmaceuticals as 2010's hot zone for mergers and acquisitions.
The five biotech ETFs have very different portfolios with markedly different performance.